The role of rifampicin in the management of cutaneous leishmaniasis
| Autor: | S K Purohit, B V Sharma, Aseri S, R A Bumb, Dhanpat K. Kochar, R D Mehta |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male medicine.medical_specialty Exacerbation Adolescent Biopsy Antiprotozoal Agents Leishmaniasis Cutaneous Placebo Gastroenterology Lesion Pharmacotherapy Cutaneous leishmaniasis Double-Blind Method Internal medicine medicine Humans Enzyme Inhibitors Adverse effect Child Aged business.industry Infant Newborn Infant Leishmaniasis General Medicine Middle Aged medicine.disease Surgery Treatment Outcome Child Preschool Female medicine.symptom Rifampin business Rifampicin medicine.drug |
| Zdroj: | QJM : monthly journal of the Association of Physicians. 93(11) |
| ISSN: | 1460-2725 |
| Popis: | We assessed the efficacy of rifampicin in the treatment of cutaneous leishmaniasis (oriental sore) using a double-blind placebo-controlled study. We studied 46 patients with cutaneous leishmaniasis, of whom 23 received rifampicin (group A) and another 23 received placebo (group B) for a period of 4 weeks. Each patient was assessed clinically for size of lesion, type of lesion, duration of lesion, number of lesions, and distribution of lesions, initially, and at the end of 1 week, 2 weeks and 4 weeks. Biochemical tests including enzyme studies were done to detect any toxic effects of the drug. Group A patients received rifampicin 1200 mg/day in two divided doses and group B patients received two doses of an identical placebo capsule. Seventeen (73.9%) of the 23 patients receiving rifampicin had complete healing. Two (8.6%) had partial healing and four (17.3%) showed no response, whereas out of 23 patients receiving placebo one patient (4.3%) showed complete healing, eight (34.7%) patients showed partial healing and 14 (60. 98%) patients showed no healing or exacerbation of lesion. The difference was statistically significant in favour of response to rifampicin. This dose of rifampicin was well-tolerated and no side-effects were seen in any patient. In cases of cutaneous leishmaniasis where injectable treatment is not feasible or not acceptable, as in cases of multiple lesions, rifampicin is a better alternative oral treatment. It is simple to administer, cheap, more effective and less toxic than other available oral drugs, and well-tolerated by patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|